Clinical trial NCT00553020: Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes
Official title: Assessment of Duration of Metabolic Effect of a Single Bolus of Subcutaneous Injected Lantus Compared to NPH-Insulin(Protaphan)in Patients With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2007-11-02
Enrollment: 16
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To assess the duration of the metabolic effect of a sc injected single dose of either insulin glargine (LantusT) or NPH-insulin (ProtaphanT) on blood glucose control in patients with type 2 diabetes


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes mellitus of either gender as defined by the American Diabetes Association (3) for more than 6 months
* BMI (as defined in Appendix A of the protocol) between 28 kg/mý and 32 kg/mý (before implementation of Amendment 1) or between 26 kg/mý and 34 kg/mý (after implementation of Amendment 1)
* Having required treatment with insulin for at least 6 months
* Stable glycemic control with glycohemoglobin (HbA1c) \>7.5% and \<9.5% (before implementation of Amendment 1) or \>7.0% and \<9.5% (after implementation of Amendment 1
* Fasting serum C-peptide \>0.2 pmol/mL. According to Amendment 3, five additional subjects with "low" (defined as less than or equal to 0.4 pmol/mL) and 5 subjects with "high" (defined as \>0.4 pmol/mL) fasting C-peptide were to be enrolled.
* Negative pregnancy test in female subjects of childbearing potential (only for those who were not surgically sterile or who were less than 2 years postmenopausal) at the beginning of the study
* No findings in medical history and physical examination (cardiovascular system, chest and lungs, thyroid, abdomen, nervous system, skin and mucosae, and muscular-skeletal system) which were clinically relevant and interfering with the conduct of the study
* Normal ECG, blood pressure, pulse rate and core body temperature unless the investigator considered an abnormality to be clinically irrelevant and not interfering with the conduct of the study

Exclusion Criteria:

* Subjects with "brittle" diabetes or predisposition to severe hypoglycemia, e.g. 2 or more severe hypoglycemic episodes (i.e. requiring assistance of another person) within the past year, or any hospitalization or emergency room visit due to poor diabetic control within the past 6 months
* Subjects who had been treated with insulin with a total insulin dose of \>1.5 IU/kg/day
* Pregnant and nursing women
* Female subjects of childbearing potential (those who are not surgically sterile or who are less than 2 years postmenopausal) unwilling or unable to use reliable contraceptive measures. Reliable contraceptive measures included the following: systemic contraceptive (oral, implant, injection), diaphragm with intravaginal spermicide, cervical cap, intrauterine device, or condom with spermicide.
* Any condition requiring the regular use of any medication if the regular use of this medication interfered with the study conduct
* Abuse of alcoholic beverages (as defined in Appendix B of the protocol)
* Treatment with oral antidiabetic drugs within the last 4 weeks
* Treatment in the previous 3 months with any drug known to have a well-defined potential for toxicity concerning vital organs
* Symptoms of any major internal medical disease in the 4 weeks before the study which, according to the investigator's opinion, could interfere with the purposes of the study
* History of hypersensitivity to any drugs that have a similar chemical structure to the study drug
* History or presence of gastrointestinal, liver, or kidney disease or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
* Blood donation during the previous 3 months
* Positive HIV- or hepatitis B/C-test
* Progressive fatal disease

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: To assess the duration of the metabolic effect of a sc injected single dose of either insulin glargine (LantusT) or NPH-insulin (ProtaphanT) on blood glucose control in patients with type 2 diabetes
timeFrame: during the study conduct
Secondary outcomes:
measure: To evaluate the effect of insulin glargine (LantusT) and NPH-insulin (ProtaphanT) on suppression of endogenous glucose production, endogenous insulin secretion, and lipolysis
timeFrame: during the study conduct
Other outcomes:
Locations:
Study officials:
affiliation: Sanofi
name: Karim El-Haschimi
role: STUDY_DIRECTOR
References: